Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion

被引:279
作者
Van Ginderachter, Jo A. [1 ]
Movahedi, Kiavash [1 ]
Ghassabeh, Gholamreza Hassanzadeh [1 ]
Meerschaut, Sofie [1 ]
Beschin, Alain [1 ]
Raes, Geert [1 ]
De Baetselier, Patrick [1 ]
机构
[1] Vrije Univ Brussel VIB, Cellular & Mol Immunol Lab, Dept Mol & Cellular Interact, B-1050 Brussels, Belgium
关键词
alternative activation; classical activation; macrophages; cancer progression; myeloid suppressor cells; tumor-associated macrophages;
D O I
10.1016/j.imbio.2006.06.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mononuclear phagocytes often function as control switches of the immune system, securing the balance between pro- and anti-inflammatory reactions. For this purpose and depending on the activating stimuli, these cells can develop into different subsets: classically (M1) or alternatively (M2) activated mononuclear phagocytes, the molecular and functional characterization of which is a current topic of investigation. Accumulating evidence suggests that cells of the monocyte/macrophage lineage can be hijacked by tumors for their own benefit. Either as immature cells in the periphery, or as mature macrophages at the tumor site, mononuclear phagocytes are able to influence the behavior of cancer cells, shape the tumor microenvironment and subvert anti-tumor immunity, thereby contributing to tumor growth and progression. This review focuses on the mechanisms behind monocyte/macrophage-mediated tumor promotion and interprets the available data within the M1/M2 conceptual frame. (c) 2006 Elsevier GmbH. All rights reserved.
引用
收藏
页码:487 / 501
页数:15
相关论文
共 136 条
[31]   Alternative activation of macrophages [J].
Gordon, S .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (01) :23-35
[32]  
Gough MJ, 2001, CANCER RES, V61, P7240
[33]   Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages [J].
Gratchev, A ;
Kzhyshkowska, J ;
Utikal, J ;
Goerdt, S .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2005, 61 (01) :10-17
[34]   Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection [J].
Guiducci, C ;
Vicari, AP ;
Sangaletti, S ;
Trinchieri, G ;
Colombo, MP .
CANCER RESEARCH, 2005, 65 (08) :3437-3446
[35]   Interferon-γ augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells [J].
Hisamatsu, T ;
Suzuki, M ;
Podolsky, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (35) :32962-32968
[36]   Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host [J].
Huang, B ;
Pan, PY ;
Li, QS ;
Sato, AI ;
Levy, DE ;
Bromberg, J ;
Divino, CM ;
Chen, SH .
CANCER RESEARCH, 2006, 66 (02) :1123-1131
[37]   Tumor rejection by disturbing tumor stroma cell interactions [J].
Ibe, S ;
Qin, ZH ;
Schüler, T ;
Preiss, S ;
Blankenstein, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (11) :1549-1559
[38]  
Ikemoto S, 2003, ONCOL REP, V10, P1843
[39]   Nitric oxide synthase inhibition by NG-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors [J].
Jadeski, LC ;
Lala, PK .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1381-1390
[40]   PPAR-γ agonists inhibit production of monocyte inflammatory cytokines [J].
Jiang, CY ;
Ting, AT ;
Seed, B .
NATURE, 1998, 391 (6662) :82-86